What analysts say:
- Buy, sell, or hold?: The majority of analysts back Regeneron Pharmaceuticals as a buy. But with 61.5% of analysts rating it a buy, it's still below the mean analyst rating of its nearest 10 competitors, which average 62% buys. Analysts like Regeneron Pharmaceuticals better than competitor Bristol-Myers Squibb overall. Thirteen out of 27 rate Bristol-Myers Squibb a buy, compared with eight of 13 for Regeneron Pharmaceuticals. While analysts still rate the stock a moderate buy, they are a little more optimistic about it compared with three months ago.
- Revenue forecasts: On average, analysts predict $121.6 million in revenue this quarter. That would represent a rise of 4.9% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is a loss of $0.41 per share. Estimates range from a loss of $0.59 to a loss of $0.22.
What our community says:
CAPS All-Stars are solidly backing the stock, with 80.8% granting it an "outperform" rating. The community at large concurs with the All-Stars, with 81.4% giving it a rating of "outperform." Fools are bullish on Regeneron Pharmaceuticals, though the message boards have been quiet lately, with only 65 posts in the past 30 days. Regeneron Pharmaceuticals' bearish CAPS rating of two out of five stars falls short of the Fool community's sentiment.
Revenue has now gone up for three straight quarters.
Now let's look at how efficient management is at running the business. Traditionally, margins represent the efficiency with which companies capture portions of sales dollars. The following table shows gross, operating, and net margins over the past four quarters.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.